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Abstract 
The purpose of this project was to improve the rate of successful human papilloma virus (HPV) 
screening in a small Texas based Women's Health clinic through co-testing. The intended goal 
was to increase the rate of HPV screening from a 73% baseline to 95% over a 10-week period for 
women aged 30–65 years old. Approximately 79 million American women are currently infected 
with HPV, and 14 million people contract it every year. Seventy percent of cervical cancers 
today are caused by HPV, with an estimated 12,820 new case of invasive cervical cancer 
expected to be diagnosed by the conclusion of 2017. Moreover, in this same year, and estimated 
4,210 American women are expected to die from HPV-related complications. Women between 
the ages of 30 and 65 years are eight times more likely to contract invasive cervical cancers 
through HPV than those under 30 years. Therefore, this project incorporated multiple 
interventions, including increased patient screening appointments, the initiation of quality 
improvement meetings, and the implementation of the HPV co-testing protocol. Upon 
completion, 107 patients between the ages of 30 and 65 had been successfully co-tested for HPV, 
with 104 patients having negative screening results, and three patients with positive results. 
There was a statistically significant improvement in the rate of HPV screening, from 73% to 
93%. Therefore, the implementation of co-testing had a positive impact on HPV screening rates. 
Keywords: human papilloma virus, HPV, cervical cancer, co-testing, women. 
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The human papillomavirus (HPV) is a viral infection that is spread through physical 
contact. HPV infections are the most prevalent sexually transmitted diseases (STD) in the world, 
and are associate with significant economic and physical burden (Miranda et al., 2013). Patients 
who have HPV and persistently become infected are at an elevated risk for many types of 
cancers, including cervical, anal, vulvar, vaginal, and oropharyngeal (Miranda et al., 2013). 
Primary care clinics need to treat these infections effectively, but with many infections having no 
major symptoms, screening for HPV is critical effective for treatment and prevention. This 
project aims to introduce the most current national HPV screening guidelines into a small 
women’s health clinic in hopes of improving HPV screening rate. 
Statement of the Problem 
The prevalence of STDs is one of the most underestimated factors in the public health 
battle (Centers for Disease Control and Prevention [CDC], 2016a). Approximately 110 million 
people living in the US are currently living with an STD (CDC, 2016). The prevalence of HPV 
has been steadily increasing, which is especially problematic for women over the age of 35, who 
suffer more severe health complications than younger patients (CDC, 2016).  
Background and Significance 
The ramifications of untreated STDs are immense. Short-term effects of untreated STDs 
include pelvic inflammatory disease, epididymitis, and pregnancy complications (Royer et al., 
2013). Long-term, STDs can result in ectopic pregnancies, infertility, urethritis, and an increase 
in the risk of contracting HIV (Royer et al., 2013). Untreated HPV can cause oral and upper 
respiratory lesions, genital warts, and cancer of the cervix, throat, female genitals, and the anus 
(CDC, 2016). One of the most concerning aspects of HPV is that while it is less common in 
women over the age of 30, when found, it is more likely to cause significant health problems, 
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such as cancer (CDC, 2012). Statistics show that fewer than 2 out of 100,000 women under the 
age of 30 contract cervical cancer, while women above the age of 30 are 8 times more likely to 
be diagnosed with cancer (CDC, 2012). 
With all of these potential complications, adequate screening is imperative for the health 
of these patients. With millions of new sexually transmitted infections occurring every year in 
America, the medical costs to the U.S. economy are tremendous. Research has found that the 
19.7 million recorded cases of STIs in 2008 cost the nation somewhere between $11 and $20 
billion, with HPV trailing only HIV at nearly $3 billion (Owusu-Edusei et al., 2013). Owusu-
Edusei et al. (2013) go on to acknowledge the importance of screening in keeping costs down, 
noting that if it were not for current screening efforts, billions more dollars would need to be 
spent on these patients. Other research has shown that screening is effective in reducing the 
physical and financial burden of HPV to the nation, especially in at-risk populations, such as 
minorities, the impoverished, and those living in high crime areas (Owusu-Edusei & Doshi, 
2012; Satterwhite et al., 2013). Missing or incorrectly performing screening procedures can incur 
a heavy burden on both the nation and on individual patients; therefore, primary care clinics need 
to prioritize these interventions (Owusu-Edusei & Doshi, 2012; Satterwhite et al., 2013). A new 
method, a co-testing procedure involving a traditional Pap smear and HPV screening, has 
become increasingly popular in primary care as a potential solution to the aforementioned 
screening difficulties (Stoler et al., 2011). 
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Assessment 
The setting for this project and where these assessments were performed was in a clinic 
located in San Antonio, Texas. Surrounding institutions and locations include San Antonio 
College, a major hospital, and a public park. The clinic was located in one of the outermost 
wings of the hospital, and was independently run by one physician. In addition to the one 
physician, the clinic was staffed by four medical assistants. Each medical assistant had the ability 
to perform the necessary procedures articulated within their scope of practice, such as 
administering injections, drawing blood, ordering supplies and equipment, preparing exam 
rooms, scheduling appointments, recording vital signs, and recording patient medical histories.  
The patient population was predominantly Caucasian (42%), followed by 
Hispanic (31%), Asian (Hindu-Indian) (12%), African American (13%), and Asian 
(Oriental) (2%). The average patient age was 38 years old, with a median age of 36 years, 
and a range from 12 to 71 years of age. The clinic’s patient population was almost 
entirely female (94%), and the majority of patients have insurance, as Medicare, 
Medicaid, nor Tricare insurances are not accepted by the clinic. The most common 
insurance provider was Blue Cross Blue Shield (37%), followed by United Health (29%), 
Aetna (15%), Humana (8%), Signa (7%), and Oscar (4%). The most common individual 
diagnoses included submucous/intramural leiomvoma of uterus, menopausal and female 
climacteric states, supervision of high risk pregnancy, and irregular menstruation.  
The clinic physician completed hospital rounds prior to arrival at the clinic on Monday, 
Tuesday, Thursday, and Friday. The physician reserved Wednesday mornings for performing 
surgeries and procedures at the hospital before arriving at the clinic later in the day  
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The duration of each appointment/examination varies by patient encounter. For general 
gynecological encounters, the physician spent on average 3 minutes, while and ultrasound or 
appointment for a pellet procedure took as long as 15 minutes. The clinic utilized a flexible and 
easy to use Microsoft Word template for recording patient appointments. The paper charting 
system used by the clinic is less efficient than using an electronic medical record. Consequently, 
there was often a backlog of documentation, with the physician spending approximately 1 hour 
each day completing their documentation before leaving the clinic. Virtually every element of 
the clinic was affected by a lack of technology, from paper charting to the use of obsolete 
equipment. The ultrasound machine was fairly new, as was the mobile card reader that allowed 
patients to pay for services with a credit card. This card reader was a relatively new device to the 
clinic, with patients previously required to pay using either cash or check. The clinic held no 
staff meetings, and the only time that the staff formally met was when a representative from a 
pharmaceutical presented a new product. There were no quality improvement checks or 
initiatives undertaken by the clinic, due in part to the nature of the clinic’s workload. When 
interviewed, none of the staff could identify areas of the clinic’s practice requiring quality 
improvement or a need for evidence-based practice. 
Clinic appointments were scheduled to commence at 10:00 a.m. With only the one 
provider for the clinic, any delays, irrespective of their source, had a snowball effect on the entire 
day, often resulting in long patient wait times. The physician usually arrived after 10:30 a.m., 
and was called out of the office on average two days out of the week to deliver babies or to 
perform other procedures. From the encounters and procedures observed, only 77% occurred 
without interruption. The physician had to leave the room to request or to personally retrieve 
necessary supplies during 45% of procedures. In summary, the days rarely went as scheduled 
HPV CO-TESTING FOR WOMEN AGED 30-65 IN AN OB/GYN 11 
owing to various interruptions; consequently, patients were usually not seen until at least 1 hour 
after their scheduled appointment time. The unpredictable nature of the clinic’s schedule means 
that there were periods in which the staff was extremely busy, which was then be followed by 
periods of relative inactivity when the physician departed for the hospital for a procedure.  
In the fall of 2016, a microsystem assessment was performed of the clinic’s 
processes and it was determined that STD screening, particularly HPV screening, was not 
being completed in accordance with clinical practice guidelines. Of the 46 eligible 
patients identified through chart reviews, only 33 (72%) had an annual HPV screening 
completed. 
Organization's Readiness for Change 
The staff’s level of readiness for the project was determined through the use of the 
Practice Improvement Capacity Rating Scale (Robert Wood Johnson Foundation, 2014). 
This assessment is well-known in health care for its ability to identify the readiness of 
personnel for performing quality improvement tasks (Robert Wood Johnson Foundation, 
2014). The assessment was completed through an interview with the physician and each 
of the clinic’s staff. After averaging the scores from all interviews (Table 1), the final 
score of 260 indicates the clinic’s readiness for quality improvement initiatives.  
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Table 1 
Results of Practice Improvement Capacity Rating Scale 










1 3 Commitment: Senior 
Leadership QI 
Champion sponsor 
Can you tell me about the 
commitment that senior leadership 
(the administration/the practice) 
has made to the project? 
 Designated leader? 
 Regular team 
meetings? 
 Time, finances, 
resources? 
  10 30 
2 3 Commitment: 
Financial Resources 
How do the leader and the QI team 
fit in QI work with their other 
responsibilities in the practice? 
  10 30 
3 3 Level of Physician 
Leader Support 
Do you have a physician leader 
who supports this effort?  
What is the relationship between 
this person and the QI team? 
  10 30 
4 3 Level of Practice 
Administrator 
Support 
Does your practice administrator 
or office manager support this 
effort? 
  10 30 
5 3 Competing Priorities Are there any changes that have 
occurred/are going to occur that 
may have an effect on this project? 
Are there any other projects the 
practice will be working on while 
this QI project is going on?  
  10 30 
6 2 Communication Does the rest of the staff know 
about this effort? 
How are you communicating the 
work being done by the QI team to 
the rest of the practice?  
  10 20 
7 2 Access/ Use of QI 
Infrastructure/ 
Resources Available 
in the Community 
Does your practice participate in 
any community improvement 
efforts? 
Any EMR sponsored or trade 
industry sponsored improvement 
efforts? 
0   0 
8 2 Prior Experience 
Executing QI 
Projects 
Tell me about the improvement 
work your practice has done in the 
past. 
What kind of experience do the 
members of the QI team bring to 
the effort? 
Do you keep a record of what you 
have tried and how it went? 
0   0 
9 2 QI team designated 
with appropriate 
representation 
Who is/ will be on your QI team? 
Why? 
  10 20 
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10 2 Reliability of data How reliable do you think your 
reports are? 
Does the information seem 
accurate to you? 
Do you compare your data to other 
national benchmarks? 
Is there someone who looks one 
the reports for accuracy? 
10 20 
11 2 Reliability of data 
collection 
How reliable do you think your 
data are?  
Do you think the data you need are 
reliably entered into the EMR with 
each encounter? 
Is there a way to tell if they are? 
10 20 




Payers Linked to the 
QI Project 
Is the practice being paid to 
participate in an improvement 
effort other than MU? 
Are you being paid to report on or 
met quality measures? 
10 20 
13 1 Meaningful Use Where is your practice in terms of 
applying for meaningful use? 
5 5 
14 1 Source of IT support What do you do when you need to 
add fields to collect data or run 
reports?  
 Do you do this in
office?
 Do you need to contact
someone outside the 
office?
 Does this arrangement
meet your needs/ the 
needs for the QI project
and QI team?
0 0 






What data will you be collecting 
for this project? How do you plan 
to collect the data you will need 
for this project? 
 Is the information 
currently collected in
your EMR? 
 Can you get reports











Stakeholders involved in the information gathering process included the physician, all 
clinic staff members, and the patient population. A strengths, weaknesses, opportunities, and 
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threats (SWOT) analysis can be used to assess both the internal and external factors affecting the 
clinic and is used as part of the readiness assessment (Nelson, Batalden, Godfrey, & Lazar, 
2011). One of the strengths of the clinic was the staff’s eagerness to try new initiatives to 
improve patient care and overall clinic efficiency. A weakness identified through the SWOT 
analysis was that the staff had been working at the clinic for many years, which may make any 
changes difficult for them to accept. An opportunity identified via the analysis was that because 
it is a private clinic, the staff was free to create their own schedule for meetings or quality 
improvement activities as they see fit, and were not bound by the schedule of another 
organization. However, one major threat to the clinic’s readiness was the lack of time due to 
double booking and low staffing, which made it difficult for the clinic to identify the time to 
enact change. Evidence-based assessments are important tasks needed to be complete by the 
clinicians in order to ensure that the highest quality of care is provided (Jensen-Doss & Hawley, 
2010). However, the lack of quality meetings in the clinic, the need to optimize patient care 
protocols and procedures is apparent, and the staff is onboard with the proposed project.  
Project Identification 
Purpose 
The purpose of this project was to improve the rate of successful HPV screening in a 
small San Antonio based clinic. Specifically, the goal was to incorporate HPV co-testing with a 
Pap smear during visits to the Well-Woman exam. This co-testing approach was added to the 
clinical guidelines of the American Cancer Society (ACS), the American Society for Colposcopy 
and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) in 
2012.  
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Objectives 
The primary objective of this project was to increase the rate of HPV screening from 73% 
currently, to 95% through HPV co-testing. Secondary objectives include increasing the average 
appointment time length from 3–5 minutes to 15 minutes for Well-Woman’s exams and to 
implement biweekly quality improvement meetings for all staff. 
Anticipated Outcomes 
Co-testing was not among the clinic’s standard practices. Standard practice was to 
conduct a Pap smear independent of any other screening procedures. While the intervention in 
this project applies to all women seen within the clinic, the primary focus of this project was 
women over the age of 30, per the recommendations in the screening guidelines. The specific 
objectives of the project included: (a) increasing the allotted appointment times for Well-
Woman’s exams; (b) improving the completion rate of all aspects of the Well-Woman’s exams, 
including HPV co-testing; and (c) initiating regular quality improvement meetings for the entire 
clinic staff. The expected primary outcome for this project will be an increased rate of HPV 
screening, which should increase from 73% to 95% over 10 weeks. Other anticipated outcomes 
include: (a) staff will attend regular quality improvement meetings, which they will conduct on 
their own after the project has been completed; and (b) appointment times for consultation and 
annual checkups will be extended.  
Summary and Strength of the Evidence 
Cancer is one of the leading causes of mortality in the United States and around the 
world. According to the CDC (2017), cancer was the second leading cause of mortality in the 
United States, causing 591,699 deaths in 2015, just behind heart disease at 614,348 deaths. To 
this into perspective, the number of cancer deaths in the US is more than the next five leading 
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causes of death combined (CDC, 2017). In 2016, 1,685,210 people were diagnosed with cancer, 
leading to 595,690 deaths (National Cancer Institute [NCI], 2017).  
Unfortunately, the global burden of cancer appears to be worsening, with there being 
little indication of improvement in the prevalence or mortality of cancer. The NCI (2017) has 
projected that worldwide cancer cases will increase by 50%, from 14 million to 21 million, 
between 2012 and 2030. Over this same period, cancer deaths across the globe are expected to 
increase by 60%, from 8 million to 13 million (NCI, 2017). The economic impact of cancer is 
substantial, with approximately $125 billion having been spent on cancer care and related 
services in 2010 (NCI, 2017). This figure is also expected to rise as the economic cost of cancer 
to the US is expected to reach $156 billion in 2020 (NCI, 2017).  
According to the ACS (2017), an estimated 12,820 new diagnoses of cervical cancer are 
expected to be made in 2017, resulting in the deaths of 4,210 women. The cost of cervical cancer 
was approximately $1.3 billion in 2010, with this figure expected to increase to $1.7 billion in 
2020 (NCI, 2017). Cervical cancer most commonly occurs in midlife, with the majority of cases 
found in women aged 20–50 years (NCI, 2017). HPV is significantly related to cervical cancer, 
with HPV being responsible for 70% of all cases (NCI, 2017). Although cervical cancer was 
once among the deadliest forms of cancer, the introduction of Pap smear testing 60 years ago has 
seen the cervical cancer death rate decrease by over 50% since the 1940s. Part of the reason for 
this dramatic reduction in cervical cancer mortality rests with the regularity of screening, the rate 
of which depends on the patient profile (usually every 1–3 years or 1–5 years) (ACS, 2017). 
Regular screening also increases early detection, which is important in light of the difficulty of 
treating advanced forms of cervical cancer.  
HPV CO-TESTING FOR WOMEN AGED 30-65 IN AN OB/GYN 17 
 
Nonetheless, the screening protocols for cervical cancer have recently changed. In early 
2012, new guidelines were jointly created by the ACS, ASCCP, and ASCP in regard to the 
prevention of and screening procedures for cervical cancer. The new guidelines recommend that 
co-testing with the HPV test, or the HPV reflex screening, is the preferred screening method 
rather than a standalone Pap smear test in patients aged 30–65 (ACS, 2017; Agency for 
Healthcare Research and Quality [AHRQ], 2012; ASCCP, 2016). This recommendation is based 
on clinical research showing that incorporating the HPV test into the cytology of the specimen 
improves the detection rate of cervical cancer and decreases the frequency in growth of invasive 
cervical cancers compared to using only a Pap smear (ACS, 2017; AHRQ, 2012; ASCCP, 2016).   
A large clinical trial conducted by the Addressing the need for advanced HPV diagnostics 
group (ATHENA) investigated the effectiveness of HPV co-testing in over 47,000 women, 
examining both women with atypical squamous cells of undetermined significance (ASC-US) 
and normal cervical cytology (Stoler et al., 2011). Upon their initial visit, study participants had 
co-testing performed, with their next follow-up appoint scheduled 3-years later (Stoler et al., 
2011). Women who tested positive at either initial or follow-up appointment were promptly 
referred to either further investigation (i.e., colposcopy) and/or treatment (Stoler et al., 2011). 
The results of this study showed that concurrent HPV testing alongside a Pap smear yielded 
more accurate results than Pap smear testing alone, improving both the detection of cervical pre-
cancer cells and invasive cancer (Stoler et al., 2011). The study was one of the largest in this 
field, and the findings were instrumental in the development of new cervical cancer screening 
guidelines developed by the ACS, ASCCP, and the ASCP. 
Cox et al. (2013) compared different cervical cancer screening methods against one 
another in relation to participants over the age of 30. Some of the strategies measured included 
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cytology with reflex HPV, co-testing with reflex for ASC-US, co-testing with genotyping and 
cytology triage, and cytology alone (Cox et al., 2013). The results of the study showed that while 
elaborate screening protocols offered greater sensitivity, they also required additional workups, 
including colposcopies that can be costly to the patient and the health care system. The study 
found that incorporating HPV testing into cervical cancer screening represented the most 
efficacious balance between achieving a high level of sensitivity and potential over-servicing 
through unnecessary screening and additional colposcopies (Cox et al., 2013).  
The ACS performed two cohort studies to determine the value of HPV co-testing with 
Pap smears. These studies involved approximately 1,065,723 women seen through the Kaiser 
Permanente Northern California facility (Silver et al., 2016). The first cohort, or “open cohort,” 
involved women who were screened for cervical cancer at KPNC between the years of 2003 and 
2012 (Silver et al., 2016). The second cohort, or the “closed cohort,” comprised women who had 
begun co-testing in 2003, and who were followed through to 2012 to determine the effect of 
repeated screenings over time (Silver et al., 2016). The average age of women participating in 
the study was 44 for the open cohort and 46 for the closed cohort. The participants were assessed 
at three time intervals: 2004–2006, 2007–2009, and 2010–2012 (Silver et al., 2016). The results 
for the open cohort showed that the detection of cervical cancer increased throughout the length 
of the study, increasing from 82 out of 100,000 women screened in the 2004–2006, to 126 out of 
100,000 women screened 2010–2012 (Silver et al., 2016). The results for the closed cohort also 
showed improvement across the duration of the study, with the largest increase occurring 
between the years of 2004 to 2006, and 2007 to 2009, during which the number of women 
screened rose from 80 out of 100,000 to 118 out of 100,000 women (Silver et al., 2016). The 
study concluded that co-testing decreased the pre-cancer and cancer rates in both samples, and 
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that co-testing is effective in reducing the burden of cervical cancer places on society (Silver et 
al., 2016).  
Another study attempted to incorporate the new co-testing guidelines into practice at a 
large health care facility (Katki et al., 2013). Through a process of benchmarking, the 
investigators changed the facility’s protocols to co-testing based on risk thresholds and 
educational efforts (Katki et al., 2013). The investigators analyzed the most critical aspects of the 
co-testing procedure and developed a study protocol with view toward increasing the 
effectiveness of screening. Health care facility staff received education regarding the significance 
of screening and the importance of the protocol for ensuring compliance. Over 965,359 patients 
were sampled over 7-year study period, from 2003 to 2010, with 100% of participants having 
been assessed for compliance using the new screening protocols (Katki et al., 2013). The types of 
cancer cells assessed included low-grade squamous intraepithelial lesions (LSIL), ASC-US, and 
HPV positive/ASC-US (Katki et al., 2013). The results of the study suggest that benchmarking 
was an effective strategy for incorporating co-testing into the targeted health care setting, and 
that co-testing reduced the risk of inaccurate screenings by as much as 80% (Katki et al., 2013).  
Arriaga et al. (2013) investigated the effects of a protocol for increasing the performance 
of operating rooms. Seventeen operating room teams from three different institutions participated 
in 106 simulated crisis situations. These teams were selected at random, with half of the 
participating teams performing the simulations without a crisis protocol, and the other half with 
crisis protocols (Arriaga et al., 2013). The results of the study showed that the teams who used 
the crisis protocols omitted only 6% of processes, while teams who were not using the crisis 
protocols omitted 23% of processes (Arriaga et al., 2013). These results were verified through a 
multivariate model that accounted for the composition of the teams, institutional habits or bias, 
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specific scenarios, and study fatigue (Arriaga et al., 2013). In addition, 97% of participating 
teams indicated that they would want to use the crisis-specific protocols in future scenarios 
(Arriaga et al., 2013).  
Protocols have also proven useful in large scale situations. A stepped wedge cluster 
randomized controlled trial published in the Annals of Surgery sought to identify the effect of a 
safety protocol for a variety of hospital procedures (Haugen et al., 2015). The trial took place in 
Norway, in both a 1,100 bed tertiary teaching hospital and a smaller 300 bed community 
hospital. Over the course of the month long trial, 2,212 control procedures and 2,263 protocol 
procedures were documented. The specialties involved in the study included cardiology, 
neurology, orthopedic, urology, and general medicine (Haugen et al., 2015). The protocol 
consisted of 20 items derived from the World Health Organization’s guidelines for safety, and 
the study sought to measure the effect of this protocol on the frequency of complications, mean 
length of stay, and in-hospital mortality (Haugen et al., 2015). The results showed significant 
positive outcomes across all variables under observation. Complication rates dropped from 
19.9% to 11.5%, mean length of stay decreased by 0.8 days, and in-hospital mortality decreased 
from 1.9% to 0.2% following procedures that utilized the protocols (Haugen et al., 2015). The 
study concluded that targeted protocols can have a positive effect on patient outcomes in large 
health care systems. 
Methods 
The primary aim of the project was to implement HPV co-testing for women aged 30–65 
years. The objectives included increasing the rate of HPV screening from the current level of 
73% to 95% through HPV co-testing, increasing the average appointment duration from 5 to 15 
minutes for Well-Woman’s exams, and implementing biweekly quality improvement meetings 
HPV CO-TESTING FOR WOMEN AGED 30-65 IN AN OB/GYN 21 
 
for all staff. Outcomes that were subject to measurement during this project included protocol 
utilization per eligible patient, percentage of protocol completed by staff per co-testing 
procedure, percentage of correctly altered time slots, and overall HPV screening rate. 
Project Intervention 
The HPV co-testing initiative included three major interventions. The first of these major 
interventions was to standardize the appointment time slots for Well-Woman exams to 15 
minutes. Prior to project initiation, patients were allocated 5-minute appointments, regardless of 
the encounter type. The inability to differentiate between the time requirements in the 
appointment template for various encounters impacted the overall organization of the clinic’s 
work practices and increased the likelihood for errors. By increasing the appointment times for 
Well-Woman exams, global improvements to the patient’s encounter experience are expected, 
from completion of the entire exam to proper specimen collection.  
The second intervention involved the initiation of quality improvement meetings in the 
clinic. These meetings are scheduled to be held on the first and third Tuesday of the month, as 
agreed upon by the staff. These meetings should help the clinic staff to focus on the resolution of 
clinical issues that might otherwise be impossible for a single person to resolve. Quality 
improvement programs are valuable components of primary care clinics (U.S. Department of 
Health and Human Services, 2011). Positive outcomes from a quality improvement program 
include improved patient health outcomes, increased efficiency in managerial processes, cost 
reductions due to a drop in preventable errors, enhanced communication between staff, and the 
ability to solve problems before they cause serious damage to the clinic (U.S. Department of 
Health and Human Services, 2011). Effective quality improvement should be considered integral 
to the management of any clinic, with such program benefiting the organization as a whole. 
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The final intervention involved the development of a protocol to guide the clinic’s staff in 
the enactment of HPV co-testing. In addition to these new co-testing guidelines, a protocol was 
introduced to be following during every eligible visit to ensure that all steps involved in the HPV 
co-testing process were performed correctly. The co-testing procedure uses the same sample 
collected for the regular Pap smear. Consequently, patients undergoing co-testing are tested for 
both cervical cancer cells and/or cervical cell changes, plus HPV via a single sample. The clinic 
is associated with and utilized the co-located hospital laboratory for pathology purposes; 
therefore, requesting HPV testing was simply a matter of adding an additional laboratory work 
order for the original Pap smear sample. Similar protocol processes have proven effective in 
larger health care system, including perioperative environments and hospital settings (Arriaga et 
al., 2013; Haugen et al., 2015; Katki et al., 2013). These studies demonstrated that the protocols 
resulted in less errors being made, enhanced the efficiency of specified processes, and increased 
effectiveness, thus leading to improved outcomes, all of which would benefit the clinic. 
The instituted protocol was composed of seven steps for completion by clinic staff during 
eligible patient encounters. These seven steps are described thusly. 
1) Verify that the appointment time slot has been changed from 5 minutes to 15 minutes. 
2) Confirm that the charts have been prepared in advance and checked the day before the 
appointment. 
3) Ensure all exam rooms have been supplied with sufficient stock of appropriate 
materials and that specimen labels have been created before the procedure begins.  
4) Staff to verify patient eligibility for HPV co-testing/screening before the encounter. 
5) Staff to ensure that all charting of the Well-Woman’s exam has been completed 
before the end of the day. 
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6) Verify that specimens have been correctly labeled and prepared for transport and 
submission to the laboratory. 
7) Staff to ensure that the next patient in the queue eligible for HPV co-testing is 
identified in advance and that their appointment time has been recorded.  
The investigator guided the staff in how to properly complete the protocol at the beginning of the 
project, with the goal that the staff would be able to complete the protocol independently as the 
project progressed. 
Copies of the protocol were posted in every examination room. The medical assistant 
responsible for assisting the physician would use the protocol during the examination and mark 
the boxes after each task was completed. Staff were instructed that should the protocol not be 
completed during a single visit, that the tick boxes for the yet to be completed tasks should be 
left blank, and the protocol placed in the front of the patient’s chart once the encounter had 
ended. At the close of the project, projected protocol utilization should be somewhere in the 
order of >90%. Another projected outcome is for >90% of protocols to be successfully 
completed by the end of the project. A third projected outcome is that over 75% of eligible 
patient appointment times will be altered from 5 minutes to 15 minutes at the close of the project. 
Finally, overall HPV screening rates are projected to rise above 90% by the end of the project.  
Results 
A total of 104 eligible patients entered the practice during the 10 weeks of the project. Of 
these, 104 (100%) were screened utilizing the HPV co-testing method. There was little 
fluctuation over the course of the project in the number of patients screened.  
Participants in this project tended to be middle-aged (Table 2), as was typical for this 
clinic as a whole. Other than Hispanic, the clinic saw a large number of women from the Hindu-
Indian population, much higher than other clinics in the San Antonio area. This may be due in 
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part to the provider’s ability to speak fluent Hindi, the provider’s native language. The clinic’s 
entire patient population was insured, with the majority of patients covered under Blue Cross 
Blue Shield (Table 2). 
Table 2 
Demographics for Well-Woman Appointments 
Age M SD 
 47.1 8.7 
Ethnicity n % 
White Non-Hispanic 47 45 
Black Non-Hispanic 6 5.8 
Asian (Hindu-Indian) 19 18.3 
Asian (Oriental) 2 1.9 
Hispanic 30 28.8 
Insurance n % 
United Health Care 40 38.5 
Blue Cross Blue Shield 43 41.3 
Aetna 11 10.6 
Humana 10 9.6 
 
Data evaluations took place at pre-intervention, mid-intervention, and post-intervention 
intervals. This research protocol allowed for changes in outcomes as a direct result of the 
intervention to be captured. Moreover, the staff’s familiarity with the intervention and new 
processes developed over time and the protocol for data analysis needed to capture these 
changes. The staff indicated having become more accustomed to the co-testing approach over the 
HPV CO-TESTING FOR WOMEN AGED 30-65 IN AN OB/GYN 25 
 
course of the project, with the data reflecting an improvement in protocol completion rates over 
the course of the project (Table 3).  
 
Table 3 
Protocol Completion Rate for Well-Woman Appointments 
Measure        Weeks 1-3        Weeks 4-7        Weeks 8-10 
Number of patients 
seen for Well-
Woman appointments 
35 35 34 
Number of correctly 
completed protocols 
16(46%) 25(71%) 32(94%) 
 
Increasing the standard patient appointment allocation to 15 minutes was the first element 
of the project. Over the course of the project, the number of time slots allocated in the schedule 
template for Well-Woman exams went from 45% to 84%. This indicates a 39% increase over the 
course of the project (Table 4).  
 
Table 4 
Changes in Appointment Allocation Time for Well-Woman Appointments 
Measure        Weeks 1-3        Weeks 4-7        Weeks 8-10 
Number of patients 
seen for Well-
Woman appointments 
35 35 34 




13(45%) 23(66%) 29(84%) 
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Before the project began, the clinic correctly screened 73% patients aged between 30 and 
65 years for HPV. The goal of the project was to increase that screening figure to 95%. At the 
end of the project, 93% of eligible patients had been correctly screened for HPV (Table 5).  
 
Table 5 
Overall HPV Screening Rate for Well-Woman Appointments 
Measure        Weeks 1-3        Weeks 4-7        Weeks 8-10 
Number of patients 
seen for Well-
Woman appointments 
35 35 34 




26(73%) 30(87%) 32(93%) 
 
Discussion 
This 10-week intervention project was completed on schedule with over 100 eligible 
patients. The project’s successes include an increase in protocol compliance, correctly allocated 
appointment slots for Well-Woman exams, and an overall increase in the rate of HPV screening. 
However, the project fell 7% short of the national guideline recommendations for HPV 
screening, with these guidelines recommending that 100% of patients be screened (AHRQ, 2012; 
ASCCP, 2016; CDC, 2012). Implementation of the protocol provided data regarding all aspects 
of the HPV screening process, with the most inaccurate aspect of the clinic’s HPV screening 
process being laboratory preparation. The staff reported that the protocol gave them greater 
confidence with the procedure. One of the main difficulties with the project was a lack of support 
from the provider, who allowed for the project rather than assisting in its implementation. This 
sentiment impacted the rest staff, with the project being met with some initial resistance. 
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However, as the project continued, the staff not only began to adhere to the protocol, but began 
to seeing benefits in the changed process. This turnaround in the attitudes of staff might be due in 
part to the meetings conducted for quality improvement and teamwork, which provided the staff 
with an opportunity to voice their complaints about internal processes and to come together on 
solutions.  
One of the main changes observed by end of the project was a change in the level of 
organization in the clinic. As previously mentioned, the lack of organization was identified as an 
impediment to the performance of everyday tasks. The HPV co-testing procedure introduced a 
more structured regimen into the clinic, especially as the project moved forward. This sense of 
structure was apparent not only in the project’s protocol, but in other clinic events, such as 
properly scheduling patient appointments, the efficient processing of referrals, and the ordering 
and stocking of supplies. The staff reported being comforted by the presence of the protocol 
because if they were to forget part of the procedure, they could refer back to the protocol for 
instruction. Another important change resulting from the project was a greater sense of teamwork 
and understanding of each staff member’s role. Prior to the commencement of the project, roles 
in the clinic were fractured and interpersonal conflicts were frequent. Ove the course of the 10-
week project, the staff grew to understand each other’s strengths, weaknesses, and goals more 
thoroughly. Again, this improvement was reported to be due to the quality improvement 
meetings, where staff felt free to express themselves and to share their ideas in a safe place.  
A major strength of the project was that it resulted in a better sense of direction for the 
staff. During pre-implementation interviews, the most common response to the question of “Do 
you have a purpose here beyond your daily tasks?” was either indifference or “No.” In post-
intervention interviews, staff reported a greater sense of purpose in the workplace, crediting this 
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change to the education that they received before the project regarding the importance of HPV 
screening, backed by statistics on its effects on the population. Most of the staff were women in a 
similar age range to participants eligible for this study; consequently, learning about HPV was 
personally relevant for them. Prior to project implementation, staff reported limited knowledge 
with regard to the significance of the tests and tasks that they performed. This greater 
understanding of the significance of their roles had a positive impact on overall clinic morale, 
which the staff reported had improved over the course of the project. 
Limitations 
There were a several cases of staff having initiated the HPV co-testing protocol with 
ineligible patients, such as those who were not in the age range or who had already completed 
recent HPV screening. In many of these cases, the protocols were completed either in their 
entirety or only partially, although co-testing was not performed. In addition, cases in which the 
patient was not successfully co-tested, regardless of protocol use, were excluded from the final 
data analysis. All of the patients involved in the study were insured, and many were willing to 
pay out of pocket for services that their insurance did not cover, such as hormone therapy. The 
relative wealth of the patient population may make it difficult to generalize project results to 
clinics that accept Medicare, Medicaid, or the uninsured. The clinic is small in terms of staff 
numbers, which made the education and implementation of the project simpler than it might have 
been with a larger clinic or health service.  
Recommendations 
The project was successful in improving the clinic’s rate of HPV screening, and for 
improving staff morale and job satisfaction. It was recommended that the clinic continue to use 
the protocol, or something similar, for maintaining the processes put in place for the Well-
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Woman exams and HPV co-testing procedures. The overall increase in the clinic’s level of 
efficiency had system-wide effects, and a similar approach could be used to improve other 
processes. Personalization of the protocol and the development of future protocols was a 
recommendation for the staff. Over the course of the project, the staff showed improved 
compliance with procedural policies and had a higher success rate in terms of being able to see 
processes through to completion. This effect might have been even more profound had the staff 
played a larger role in the development of the protocols. Ensuring appropriate appointment times 
for patient encounters was also something that made a very important to the overall efficiency of 
the clinic. It is recommended that the staff continue to schedule appointment times based on the 
nature of the case rather than a set duration for all visits. Many of the patients attending the clinic 
were up-to-date on their screenings, which may be a result of the high quality health insurance 
available to them. HPV co-testing would be just as valuable, if not more so, among populations 
lacking regular access to primary care; consequently, a national set of guidelines should be 
developed for implementation in all clinics. Additional educational activities are recommended 
for the staff and the clinic’s patients as many had a poor understanding of HPV and its effects. 
Improving the knowledge of clinic staff regarding the subject of HPV had a positive impact on 
the staff, and could be effective in motivating patients to keep up-to-date with their screenings.  
Prior to this project, the clinic was completely lacking in standardized protocols. Based 
on the state of disorganization within the clinic at pre-intervention assessment, the 
implementation of the protocol was intended to improve productivity and efficiency in terms of 
HPV co-testing and overall systems of work. The protocol was successful in improving the 
performance of the clinic with respect to HPV screening, and its implementation had a positive 
effect on staff morale, and the performance of other routine clinic/office tasks. Following the 
HPV CO-TESTING FOR WOMEN AGED 30-65 IN AN OB/GYN 30 
 
completion of this project, the staff have begun to develop similar protocols for other clinic 
activities, such as hormone therapy procedures and ultrasound exams. The staff have also 
indicated a desire to maintain the quality improvement meeting schedule following project 
completion; whereupon they hope to develop further protocols, and to address other issues in the 
operation of clinic. Notwithstanding, the provider for the clinic is not completely supportive of 
these new measures, but has tentatively agreed to allow the meetings and development of clinical 
protocols to continue.  
Implications for Practice 
PhD-prepared nurse practitioners have the ability to identify problems at both a systems-
based and procedural level. The educational preparation of these nurse practitioners ensures that 
they know how to find accurate evidence on topics pertinent to their workplaces and where to go 
looking for that evidence. Moreover, the nurse practitioners’ understanding of advance research 
theory means that they are expertly prepared to make meaning of national guideline documents 
and research articles, ranging from randomized controlled trials to single descriptive studies, 
which might occasionally overwhelm others. Having identified best practice based on evidence, 
the PhD-prepared nurse practitioner is ideally poised to spearhead the implementation of these 
best practices to improve patient and organizational outcomes. Moreover, the PhD-prepared 
nurse practitioner should be aware of the imperative to review and critique their own practices 
and results of their projects in order to determine the efficacy of such projects in terms of 
individual patient and population outcomes. Their nursing background allows the nurse 
practitioner to effectively communicate with other staff members, which is a necessary condition 
for increasing the likelihood of adherence and project morale.  
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